Delpor Inc. said today that it won a $1.5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of its exenatide implant.
The implant was designed for patients with Type II diabetes and features Delpor’s Nanopor technology, which uses passive diffusion to deliver therapeutic levels of exenatide for at least 3 months.
Get the full story at our sister site, Drug Delivery Business News.
The post Delpor wins $1.5m NIH grant for diabetes drug implant appeared first on MassDevice.